Loading…
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1.1B | $117M | $391M | $105M | 31.9% | 11.9% | 72.7% |
| 2024 | $958M | $100M | $226M | $157M | 30.9% | 31.8% | -469.5% |
| 2023 | $726M | $-68M | $-61M | $17M | -14.2% | 40.4% | -71.6% |
| 2022 | $517M | $-222M | $-216M | $-114M | -53.9% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 517.24 | 726.44 | 957.80 | 1,071.51 |
| Operating Revenue | - | 517.24 | 726.44 | 957.80 | 1,071.51 |
| Cost Of Revenue | - | 10.17 | 41.64 | 81.84 | 89 |
| Gross Profit | - | 507.07 | 684.80 | 875.96 | 982.51 |
| Operating Expense | - | 730.66 | 758.18 | 791.68 | 877.70 |
| Research And Development | - | 361.58 | 351.62 | 303.25 | 328.80 |
| Selling General And Administration | - | 369.09 | 406.56 | 488.43 | 548.89 |
| Total Expenses | - | 740.83 | 799.82 | 873.52 | 966.69 |
| Operating Income | - | -223.60 | -73.38 | 84.28 | 104.81 |
| Total Operating Income As Reported | - | -223.60 | -73.38 | 230.79 | 104.81 |
| EBITDA | - | -221.57 | -67.83 | 100.16 | 116.57 |
| Normalized EBITDA | - | -221.57 | -67.83 | -46.35 | 116.57 |
| EBIT | - | -223.60 | -73.38 | 84.28 | 104.81 |
| Interest Income | - | 6.61 | 17.23 | 25.46 | 31.72 |
| Net Interest Income | - | 6.61 | 17.23 | 25.46 | 31.72 |
| Other Non Operating Income Expenses | - | 3.54 | 5.11 | 1.82 | 2.37 |
| Other Income Expense | - | 3.54 | 5.11 | 148.34 | 2.37 |
| Interest Income Non Operating | - | 6.61 | 17.23 | 25.46 | 31.72 |
| Net Non Operating Interest Income Expense | - | 6.61 | 17.23 | 25.46 | 31.72 |
| Pretax Income | - | -213.44 | -51.04 | 258.08 | 138.90 |
| Tax Provision | - | 2.53 | 10.25 | 31.62 | -252.10 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 17.95 | 0 |
| Net Income Continuous Operations | - | -215.98 | -61.29 | 226.45 | 391 |
| Net Income From Continuing And Discontinued Operation | - | -215.98 | -61.29 | 226.45 | 391 |
| Net Income From Continuing Operation Net Minority Interest | - | -215.98 | -61.29 | 226.45 | 391 |
| Net Income | - | -215.98 | -61.29 | 226.45 | 391 |
| Net Income Common Stockholders | - | -215.98 | -61.29 | 226.45 | 391 |
| Net Income Including Noncontrolling Interests | - | -215.98 | -61.29 | 226.45 | 391 |
| Normalized Income | - | -215.98 | -61.29 | 97.89 | 391 |
| Diluted NI Availto Com Stockholders | - | -215.98 | -61.29 | 226.45 | 391 |
| Basic Average Shares | - | 161.68 | 163.82 | 165.72 | 168.36 |
| Diluted Average Shares | - | 161.68 | 163.82 | 166.36 | 169.92 |
| Reconciled Depreciation | - | 2.03 | 5.55 | 15.88 | 11.76 |
| Reconciled Cost Of Revenue | - | 10.17 | 41.64 | 81.84 | 89 |
| Total Unusual Items | - | 0 | 0 | 146.51 | 0 |
| Total Unusual Items Excluding Goodwill | - | 0 | 0 | 146.51 | 0 |
| Special Income Charges | - | 0 | 0 | 146.51 | 0 |
| General And Administrative Expense | 396.03 | - | - | - | - |
| Other Gand A | 396.03 | - | - | - | - |
| Gain On Sale Of Ppe | - | 0 | 0 | 146.51 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc.this co. | ACAD | $3.7B | 9.51↓ discount | 3.03 | 31.9% | 30.83 |
| RadNet, Inc. | RDNT | $4.2B | -222.64 | 3.81 | -1.7% | 16.71 |
| Veracyte, Inc. | VCYT | $4.0B | 60.06 | 3.04 | 5.1% | 40.86 |
| Waystar Holding Corp. | WAY | $3.9B | 34.60 | 1.00 | 2.9% | 13.55 |
| Catalyst Pharmaceuticals, Inc. | CPRX | $3.8B |
| - |
| - |
| - |
| - |
| - |
| - |
| 17.87 |
| 4.01 |
| 22.5% |
| 10.56 |
| Merit Medical Systems, Inc. | MMSI | $3.8B | 29.27 | 2.37 | 8.1% | 12.46 |
| Organon & Co. | OGN | $3.5B | 18.82 | 4.68 | 24.9% | 8.98 |
| ICU Medical, Inc. | ICUI | $3.4B | 4607.08 | 1.59 | 0.0% | 14.73 |
| Concentra Group Holdings Parent, Inc. | CON | $3.2B | 19.16 | 8.11 | 42.3% | 12.74 |
| Peer Median | - | 24.21 | 3.43 | 6.6% | 13.15 | |